Last reviewed · How we verify
NCT06704919
Conduit Cages and Fibergraft BG Putty
trial testing Use of conduit cages and fibergraft BG Putty in Degenerative Disc Disease in 100 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Nitin Agarwal |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 4 November 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 30 March 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Use of conduit cages and fibergraft BG Putty
Conditions studied
- Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
- Herniated Disc — all drugs for Herniated Disc →
Sponsor
Nitin Agarwal — full company profile →
Who can join
18 and older, any sex, with Degenerative Disc Disease or Herniated Disc. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Conduit cages are intended to restore the intervertebral height and to facilitate the intervertebral body fusion in the cervical and lumbar spine in skeletally mature patients with degenerative disc disease and instabilities at one or more levels of the spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have described the use of conduit cages in interbody fixation procedures, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, and instabilities at one to multilevel contiguous levels between C2-T1 and 1-2 contiguous levels between L2-S1 of the spine with accompanying radicular symptoms, ruptured or herniated discs, and pseudarthrosis and spondylodesis. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06704919
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Degenerative Disc Disease
Currently open trials in the same condition.
- NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
- NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting
- NCT06115512 — A Phase 3 Study of AGA111 in Patients With Degenerative Disc Disease Undergoing Lumbar Interbody Fusion · Phase 3 · active not recruiting
Other Nitin Agarwal trials
Trials by the same sponsor.
- NCT06704906 — Adult Patient Outcomes After Spine Surgery With Fibergraft BG Putty/Viper Prime · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06704919 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nitin Agarwal
- Last refreshed: 22 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06704919.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing